Nūhou
Nā Pilikia i ka Mālama ʻana i ka Maʻi Fungal Invasive Breakthrough i nā Maʻi Hematoma Malignancy: Nā ʻIke mai ASH 2024
Ma ka Hālāwai Makahiki ASH 2024, ua kaʻana like ʻo Polofesa Sun Yuqian i kāna noiʻi hou e pili ana i ka maʻi fungal invasive breakthrough (bIFD) i nā poʻe maʻi me nā maʻi hematologic malignancies, e hōʻike ana i nā pilikia diagnostics a me therapeutic, a me nā ʻike kūpono e pili ana i nā haʻawina hou.
Nā Holomua i ka T-ALL Risk Stratification: ʻIke ka hoʻokaʻawale ʻana ma muli o NGS i nā hui liʻiliʻi pilikia kiʻekiʻe
Ua paʻi ʻia kahi noiʻi hou ma Koko Hoʻomaʻemaʻe i ka hoʻokaʻawale pilikia no ka T-cell acute lymphoblastic leukemia (T-ALL) me ka hoʻohana ʻana i ka hanauna hou (NGS), e hoʻomaikaʻi ana i nā wānana prognosis a me ka ʻike ʻana i nā hui liʻiliʻi kiʻekiʻe e hiki ke pōmaikaʻi mai nā lāʻau lapaʻau i kuhikuhi ʻia.
Ka Hoʻokele ʻana i nā Pilikia Lōʻihi o ka CAR-T Therapy: Nā ʻIke mai ke Kanesa Kūlohelohe
Ua paʻi ʻia kahi noiʻi hou i loko o Ka maʻi ʻaʻai kūlohelohe hōʻike i nā pilikia lōʻihi o ka lāʻau lapaʻau CAR-T cell, e kālele ana i nā pilikia o nā maʻi a me nā maʻi malignancies lua, a hāʻawi i nā hoʻolālā e hoʻomaikaʻi i nā hopena o ka mea maʻi.
Ka Holomua Hoʻonaʻauao | Ua Paʻi ka Hui Lapaʻau ʻo Lu Daopei i kahi Haʻawina Lapaʻau Hou ma ka British Journal of Haematology
Ua paʻi ka Hui Lapaʻau ʻo Lu Daopei, i alakaʻi ʻia e Kauka Cao Xingyu lāua ʻo Polopeka Lu Peihua, i kahi pepa noiʻi lapaʻau koʻikoʻi ma ka Ka Nūpepa Pelekane o ka Hematology (Impact Factor 5.1). Ke noiʻi nei ke aʻo ʻana i ka palekana a me ka pono o ka hoʻoili ʻana o nā cell stem hematopoietic allogeneic (allo-HSCT) ma hope o ka lāʻau lapaʻau autologous CD7 CAR-T no ka leukemia lymphoblastic acute T-cell refractory a me ka relapsed (R/R T-ALL/T-LBL).
Moʻolelo o ka Mea Maʻi | Mea Ola o ka Acute Myeloid Leukemia (AML-M2): 9 Makahiki Ma hope o ke Kāpili ʻana, Ke ʻApo nei i ka Mana o ka Manaʻolana a me ka Hānau Hou ʻana
He moʻolelo hoʻoneʻe naʻau o kahi mea maʻi mai ka Halemai ʻo Lu Daopei, e hōʻike ana i ka huakaʻi a kahi kāne i ola i ka AML-M2 he 32 makahiki, ma hope o ka hana ʻana i ka hoʻoili ʻana o nā cell kumu haploidentical, e hoʻolauleʻa ana i 9 mau makahiki o ke kala ʻana, e ola ana i kahi ola piha a olaola, i hoʻoulu ʻia e ke aloha, ka manaʻolana, a me ke ahonui.
Hoʻomaikaʻi ʻia nā helu ola me Bu/Cy+Melphalan a me Bu/Cy+Thiotepa Regimens ma Haploidentical Stem Cell Transplantation no ka Non-Down Syndrome Acute Megakaryoblastic Leukemia (AMKL)
Ua hōʻike ʻia kahi noiʻi i hōʻike ʻia ma ASH 2024 e Kauka Zhi-Jie Wei a me kāna hui ma ka Halemai ʻo Lu Daopei i ka pono o nā regimens Bu/Cy-based i hoʻololi ʻia i ka hoʻoili ʻana o nā cell stem hematopoietic haploidentical no ka Non-Down Syndrome Acute Megakaryoblastic Leukemia (AMKL), e hōʻike ana i nā hopena ola maikaʻi no nā maʻi remission piha (CR).
Nā Hualoaʻa Hoʻohiki no ka CD7 CAR-T Therapy i ka Mālama ʻana i ka Relapsed/Refractory Peripheral T-Cell Lymphoma ma ASH 2024
Ma ka Hālāwai Makahiki ASH 2024, ua hōʻike ʻo Polopeka Lu Peihua mai ka Halemai ʻo Lu Daopei i nā hopena kupaianaha mai kahi hoʻokolohua Phase I o ka lāʻau lapaʻau CD7 CAR-T cell no ka relapsed/refractory peripheral T-cell lymphoma (R/R PTCL), e hōʻike ana i ka pono a me ka palekana hiki ke hoʻokele ʻia.
Ke lanakila nei i nā pilikia ma ka CAR-T Therapy no nā maʻi ʻaʻai koko T-Cell
ʻOiai ua hoʻololi ka lāʻau lapaʻau CAR-T i ka mālama ʻana i nā maʻi ʻaʻai B-cell, ke mau nei nā pilikia koʻikoʻi i ka mālama ʻana i nā maʻi ʻaʻai T-cell. Ke nānā nei kahi loiloi hou i nā paʻakikī o ka lāʻau lapaʻau CAR-T i nā maʻi ʻaʻai koko T-cell a me nā hopena kūpono e lanakila ai i kēia mau pilikia.
Nā Holomua i ka Lapaʻau Laina Mua no ka B-ALL Pākeke: He Loiloi Piha mai The Lancet Haematology
He loiloi hou i loko o ʻO ka Lancet Haematology hōʻike i ka holomua koʻikoʻi i ka mālama mua ʻana o ka maʻi B-cell Acute Lymphoblastic Leukemia makua (B-ALL) i ʻike hou ʻia, e kālele ana i nā ʻano lapaʻau pilikino, nā immunotherapies hou, a me nā hopena maʻi i hoʻomaikaʻi ʻia.
Ua Hoʻōla Hou Kekahi ʻŌpio I Ka Manaʻolana Ma Hope o ka Hōʻailona AML M4a He Huakaʻi o ke Kūpaʻa a me ka Hoʻōla
Ma hope o ke kaua ʻana me ka leukemia myeloid acute (AML-M4a) a me ke komo ʻana i kahi hoʻoili cell stem e hoʻōla ai i ke ola, loaʻa i kahi maʻi ʻōpio ka manaʻolana, ke olakino, a me kahi hoʻomaka hou, mahalo i ka mālama kūikawā o ka Halemai ʻo Lu Daopei.
Nā Holomua Hou i ka Lapaʻau a me ka ʻIke ʻana o ka Lymphoma ʻōnaehana Nervous Waena mua (PCNSL)
Ua hāʻawi ka holomua hou i ka ʻike ʻana a me ka mālama ʻana i ka Primary Central Nervous System Lymphoma (PCNSL) i ka manaʻolana hou no nā maʻi. Hōʻike kahi loiloi hou mai ke Kulanui ʻo Stanford i ke koʻikoʻi o ka ʻike mua ʻana a me nā koho lapaʻau hou loa, me ka chemotherapy a me nā therapies i kuhikuhi ʻia.
Ka Moʻolelo o ka Mea Maʻi: Ke lanakila nei i ka Leukemia Myeloid Acute a me ka hānau hou ʻana ma hope o ka hoʻoili ʻana o nā cell stem
Ke kaʻana like nei kekahi maʻi kāne 34 makahiki i kāna huakaʻi hoʻoikaika o ke kaua ʻana me ka acute myeloid leukemia (AML), ke komo ʻana i nā manawa he nui o ka chemotherapy a me ka hoʻoili cell stem, a me ka hoʻolauleʻa ʻana i ʻekolu mau makahiki o ka ho'ōla ʻana a me ka manaʻolana hou.